Royal Bank of Canada
MRTX

Royal Bank of Canada’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Royal Bank of Canada’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,831
Closed -$1.34M – 7863
2023
Q4 		$1.34M Sell
22,831
-37,433
-62% -$2.1M ﹤0.01% 3421
2023
Q3 		$2.63M Buy
60,264
+12,910
+27% +$461K ﹤0.01% 2624
2023
Q2 		$1.71M Sell
47,354
-2,408
-5% -$99.2K ﹤0.01% 2958
2023
Q1 		$1.85M Buy
49,762
+18,410
+59% +$828K ﹤0.01% 2861
2022
Q4 		$1.42M Buy
31,352
+4,841
+18% +$313K ﹤0.01% 3212
2022
Q3 		$1.85M Buy
26,511
+2,238
+9% +$166K ﹤0.01% 2922
2022
Q2 		$1.63M Buy
24,273
+10,920
+82% +$694K ﹤0.01% 3072
2022
Q1 		$1.1M Sell
13,353
-45,392
-77% -$4.64M ﹤0.01% 3570
2021
Q4 		$8.62M Buy
58,745
+49,390
+528% +$7.67M ﹤0.01% 1995
2021
Q3 		$1.66M Sell
9,355
-12,712
-58% -$2.05M ﹤0.01% 3239
2021
Q2 		$3.56M Sell
22,067
-23,192
-51% -$3.72M ﹤0.01% 2548
2021
Q1 		$7.75M Buy
45,259
+11,325
+33% +$2.24M ﹤0.01% 1934
2020
Q4 		$7.45M Buy
33,934
+922
+3% +$199K ﹤0.01% 1923
2020
Q3 		$5.48M Sell
33,012
-10,978
-25% -$1.5M ﹤0.01% 1946
2020
Q2 		$5.02M Buy
43,990
+4,578
+12% +$444K ﹤0.01% 1937
2020
Q1 		$3.03M Buy
39,412
+33,994
+627% +$3.05M ﹤0.01% 2162
2019
Q4 		$698K Buy
5,418
+1,713
+46% +$165K ﹤0.01% 3733
2019
Q3 		$289K Buy
3,705
+90
+2% +$8.45K ﹤0.01% 4212
2019
Q2 		$373K Sell
3,615
-1,165
-24% -$90.7K ﹤0.01% 4051
2019
Q1 		$351K Buy
4,780
+97
+2% +$6.6K ﹤0.01% 3987
2018
Q4 		$199K Sell
4,683
-837
-15% -$33.4K ﹤0.01% 4350
2018
Q3 		$259K Buy
+5,520
New +$307K ﹤0.01% 4341
2018
Q1 		– Sell
-99
Closed -$2K – 6919
2017
Q4 		$2K Buy
+99
New +$1.54K ﹤0.01% 6314
2017
Q3 		– Sell
-104
Closed – – 7069
2017
Q2 		$0 Sell
104
-420
-80% -$1.61K ﹤0.01% 6845
2017
Q1 		$3K Sell
524
-331
-39% -$1.81K ﹤0.01% 6374
2016
Q4 		$4K Sell
855
-1,661
-66% -$9.04K ﹤0.01% 6374
2016
Q3 		$17K Sell
2,516
-2,884
-53% -$15.3K ﹤0.01% 5607
2016
Q2 		$29K Sell
5,400
-13,850
-72% -$221K ﹤0.01% 5354
2016
Q1 		$412K Buy
19,250
+3,828
+25% +$85.6K ﹤0.01% 3808
2015
Q4 		$487K Buy
15,422
+3,684
+31% +$130K ﹤0.01% 3804
2015
Q3 		$404K Sell
11,738
-6,161
-34% -$186K ﹤0.01% 3723
2015
Q2 		$563K Buy
17,899
+147
+0.8% +$4.33K ﹤0.01% 3499
2015
Q1 		$520K Buy
17,752
+391
+2% +$9.17K ﹤0.01% 3474
2014
Q4 		$321K Buy
17,361
+7,859
+83% +$132K ﹤0.01% 3974
2014
Q3 		$167K Buy
9,502
+500
+6% +$9.33K ﹤0.01% 4305
2014
Q2 		$180K Sell
9,002
-900
-9% -$17.4K ﹤0.01% 4240
2014
Q1 		$189K Sell
9,902
-14,821
-60% -$308K ﹤0.01% 4161
2013
Q4 		$411K Buy
24,723
+1,200
+5% +$20.5K ﹤0.01% 3579
2013
Q3 		$356K Buy
+23,523
New +$231K ﹤0.01% 3656

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Royal Bank of Canada's MRTX Position: Q1 2024 in Review

Royal Bank of Canada sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 22,831 shares — an estimated $1.34M sold.

Royal Bank of Canada first reported a position in MRTX in Q3 2013 and held it in 39 quarters. The position peaked at $8.62M in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Royal Bank of Canada reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 22,831 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.34M.
  • Royal Bank of Canada first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 39 quarters.
  • Royal Bank of Canada's Mirati Therapeutics, Inc. Common Stock position peaked at $8.62M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.